Narcolepsy-Pipeline Insight, 2018 | Analytical Research Cognizance
Published by ARCDI001
Report ID 152760
Published date Oct 30, 2018
Category Pharmaceuticals and Healthcare
Total Pages 76
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

"Narcolepsy - Pipeline Insight, 2018" report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Narcolepsy. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 20+ products along with 15+ companies involved.

Products covered by Phase
Phase III, Phase II, Phase I and IND
Pre-clinical & Discovery
Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Narcolepsy
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Narcolepsy
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
Provides an overview of therapeutic pipeline activity for Narcolepsy across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Narcolepsy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
Coverage of dormant and discontinued pipeline projects across Narcolepsy

Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Narcolepsy to formulate effective R&D strategies
Assess challenges and opportunities that influence Narcolepsy R&D
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Narcolepsy to enhance and expand business potential and scope
Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
















Types of Narcolepsy
Pipeline Therapeutics
Competitive Landscape
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Solriamfetol: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Dormant and Discontinued Products
Comparative Analysis

Table 1: Total Products for Narcolepsy
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I and IND)
Table 5: Pre-clinical and Discovery Stage Products
Table 6: Assessment by Mono Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Dormant Products
Table 11: Discontinued Products
Figure 1: Pathophysiology of Narcolepsy
Figure 2: Total Products for Narcolepsy
Figure 3: Late Stage Products (Phase III)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I and IND)
Figure 6: Pre-clinical and Discovery Stage Products
Figure 7: Assessment by Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Dormant and Discontinued Products